In the cardio-oncology population, drug interactions are of particular importance given the
complex pharmacological profile, narrow therapeutic index, and inherent risk of therapies …

Abstract Background This is Part 2 of the first consensus guidelines for optimal care of
patients undergoing emergency laparotomy (EL) using an Enhanced Recovery After …

Background Despite recent improvements in the treatment of cancer, little is known about
the long-term survival in patients with cancer and venous thromboembolism. We aimed to …

Patients with cancer are at higher risk of developing venous thromboembolism (VTE)
compared with the general population. This elevated risk is due to several risk factors and …

Purpose To develop and validate machine learning (ML) models for cancer-associated deep
vein thrombosis (DVT) and to compare the performance of these models with the Khorana …

Fondaparinux sodium is a chemically synthesized selective factor Xa inhibitor approved for
the prevention and treatment of venous thromboembolic events, that is, deep vein …

Venous thromboembolism (VTE) is a major cause of both morbidity and mortality in patients
with cancer. Venous thromboembolism, which includes both deep vein thrombosis and …

Venous thromboembolism (VTE) is a frequent and potentially fatal complication in patients
with cancer. During the initial period after the thromboembolic event, a patient receiving …

Abstract Background Risk assessment models (RAMs) are relevant approaches to identify
cancer outpatients at high risk of venous thromboembolism (VTE). Among the proposed …

Cancer‐associated venous thromboembolism (VTE) is a leading cause of morbidity and
mortality in patients with cancer. Treatment of cancer‐associated VTE comes with a …